What's hot

View all perspectives
      The risk of discontinuing first line biologics was twice higher in non-radiographic female patients compared to males. A

      Antoni Chan MD (Prof) synovialjoints

      9 months 4 weeks ago
      The risk of discontinuing first line biologics was twice higher in non-radiographic female patients compared to males. Abstr#0572 @RheumNow #ACR24 https://t.co/1tQUhsbqUu
      Dhir et al. RCT of increasing folic acid from 5-10mg per week to 15-35mg per week if MTX intolerance. No benefit! Althou

      Richard Conway RichardPAConway

      9 months 4 weeks ago
      Dhir et al. RCT of increasing folic acid from 5-10mg per week to 15-35mg per week if MTX intolerance. No benefit! Although significant placebo response and folic acid is relatively benign. @RheumNow #ACR24 Abstr#0525 https://t.co/D3yfV6a8t6 https://t.co/QpDa1alvMz
      Yokose et al. Population study using NHANES. Gout patients had 1.6 higher fold risk of gallstone disease. What? Why do w

      Richard Conway RichardPAConway

      9 months 4 weeks ago
      Yokose et al. Population study using NHANES. Gout patients had 1.6 higher fold risk of gallstone disease. What? Why do we care? Well, GLP-1s associated with higher risk gallstones also... @RheumNow #ACR24 Abstr#0133 https://t.co/nf4R0hQe50 https://t.co/wDrEDeNbpT
      🧬 #SLE patients show major community mobility limits: 50% don't leave their neighborhood weekly without help. Life Sp

      Bella Mehta bella_mehta

      9 months 4 weeks ago
      🧬 #SLE patients show major community mobility limits: 50% don't leave their neighborhood weekly without help. Life Space Assessment finds lower mobility vs. other chronic conditions. Better mobility linked to higher SES & lower disease activity. @RheumNow #ACR24 abst#0145 https://t.co/2sfXNlJ9JD
      Data from the French DESIR cohort reveals no significant link between high-dose NSAID use and incident hypertension in p

      Antoni Chan MD (Prof) synovialjoints

      9 months 4 weeks ago
      Data from the French DESIR cohort reveals no significant link between high-dose NSAID use and incident hypertension in patients with axial spondyloarthritis. Two thirds were high dose NSAID users at baseline. Incident hypertension occurred in 11% individuals during follow-up.… https://t.co/EAICDwzxNT
      Courvoisier et al. JAK-pot study analysis. Which therapies work quicker in RA? JAKi (as expected) and TNFi (what!?) fast

      Richard Conway RichardPAConway

      9 months 4 weeks ago
      Courvoisier et al. JAK-pot study analysis. Which therapies work quicker in RA? JAKi (as expected) and TNFi (what!?) faster than IL6 and abatacept. @RheumNow #ACR24 Abstr#0501 https://t.co/7DPPwHlqpP https://t.co/3mOJ62hZhp
      Serrano-Combarro et al. Abatacept in RA-ILD. 343 patients. In 23.3% ILD progressed on abatacept. Is that good or bad? We

      Richard Conway RichardPAConway

      9 months 4 weeks ago
      Serrano-Combarro et al. Abatacept in RA-ILD. 343 patients. In 23.3% ILD progressed on abatacept. Is that good or bad? We need comparative studies! @RheumNow #ACR24 Abstr#0475 https://t.co/nUEDdjGguA https://t.co/sXEF72MafK
      Are you pts using cannabis?
      In Canada - 20% reported using w/in past 2 years
      Use for pain, sleep, anxiety
      78% noted effi

      Eric Dein ericdeinmd

      9 months 4 weeks ago
      Are you pts using cannabis? In Canada - 20% reported using w/in past 2 years Use for pain, sleep, anxiety 78% noted efficacy Compare to another study said 57% stopped due to inefficacy, 28% AEs - very diff result 70% did not tell their doc 16S18 @BharatKumarMD #ACR24 @RheumNow https://t.co/6NAECW5MJK
      Serrano-Combarro et al. Baricitinib in RA-ILD . 72 patient case series. PFTs in picture. HRCT stable/improved in 72% ove

      Richard Conway RichardPAConway

      9 months 4 weeks ago
      Serrano-Combarro et al. Baricitinib in RA-ILD . 72 patient case series. PFTs in picture. HRCT stable/improved in 72% over 24 months. Dyspnoea stable/improved in 90%. @RheumNow #ACR24 Abstr#0476 https://t.co/aVI2kRZkMN https://t.co/4l5GKsFKtm
      Medical cannabis in the USA today
      Variation in state practice on recreational/medical/decriminalization
      16S18 @BharatKum

      Eric Dein ericdeinmd

      9 months 4 weeks ago
      Medical cannabis in the USA today Variation in state practice on recreational/medical/decriminalization 16S18 @BharatKumarMD #ACR24 @RheumNow https://t.co/9Ex3lge6KO
      PRO-SPIRIT trial data on 1192 PsA pts showed IL-17Ai seemed better than IL-12/23i and IL-23i improving cDAPSA at 3m and

      Adela Castro AdelaCastro222

      9 months 4 weeks ago
      PRO-SPIRIT trial data on 1192 PsA pts showed IL-17Ai seemed better than IL-12/23i and IL-23i improving cDAPSA at 3m and as effective as TNFi and JAKi. No much differences seen at 12m. Abst#0076 #ACR24 @RheumNow https://t.co/dScwsmkDOe
      In the SPACE cohort, patients with chronic back pain suspected of axial spondyloarthritis often receive a diagnosis with

      Antoni Chan MD (Prof) synovialjoints

      9 months 4 weeks ago
      In the SPACE cohort, patients with chronic back pain suspected of axial spondyloarthritis often receive a diagnosis within 35 months from symptom onset. Key determinants for early diagnosis include HLA-B27 positivity and sacroiliitis on imaging. Early diagnosis can be a game… https://t.co/RrcrtRoMfL
      #0584🔬Real-World PsA Study:Tofacitinib

      ➡️141 pts:47% mono,53% combo;~70% on Rx @ 6mo

      ➡️Similar ⬆️in di

      Caoilfhionn Connolly CaoilfhionnMD

      9 months 4 weeks ago
      #0584🔬Real-World PsA Study:Tofacitinib ➡️141 pts:47% mono,53% combo;~70% on Rx @ 6mo ➡️Similar ⬆️in disease outcomes (cDAPSA LDA: 31% mono vs 21% combo; MDA ~16%). ➡️No significant differences mono v combo outcomes 🩺Tofa effective in diverse PsA population #ACR24 @RheumNow
      With many treatments for #PsA and #PsO, what are the prescribing trends?

      Abstract 0604: TNF inhibitors remain the most

      Akhil Sood MD AkhilSoodMD

      9 months 4 weeks ago
      With many treatments for #PsA and #PsO, what are the prescribing trends? Abstract 0604: TNF inhibitors remain the most common (~60%), but over the past 10 years, IL-17i use rose from 0.2% to 19%, and IL-23i from 0.1% to 39.7%! #ACR24 @RheumNow https://t.co/4TnCAkHfuY
      Cannabis and Physical Function
      Very small effects on meta-analysis

      PO cannabis - 4% benefit (0.1-8%) of achieving at le

      Eric Dein ericdeinmd

      9 months 4 weeks ago
      Cannabis and Physical Function Very small effects on meta-analysis PO cannabis - 4% benefit (0.1-8%) of achieving at least MID of SF36 function scale 16S18 @BharatKumarMD #ACR24 @RheumNow https://t.co/qQOYt1m3ub
      How well do you know this week's rheumatology news?
      Take the rheumIQ quiz
      Take the RheumIQ Quiz

      Podcasts

      • ACR24 IL-17 Topic Panel Advancing Care with IL-17 Pathway Insights
      • ACR24 JAK TYK Topic Panel
      • RheumNow Day 1 Recap ACR Convergence 2024 Highlights

      Catch up on Conference Podcasts

      ×